ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
PharmAbcine signs a research collaboration agreement with Wuxi Shuangliang Biotechnology (SLBio) to evaluate a combination therapy to treat NSCLC
August 04, 2020PharmAbcine Inc. (KOSDAQ: 208340ks) entered into a research collaboration with Wuxi Shuangliang Biotechnology (SLBio) to evaluate the combination of each party's clinical candidate, olinvacimab and C-005, a 3rd generation of EGFR inhibitor with superior b -
PharmAbcine, SLBio Enter NSCLC Research Pact
August 04, 2020To evaluate olinvacimab and C-005, a 3rd generation of EGFR inhibitor with superior brain-blood-barrier permeability in treating non-small cell lung cancer.
Pharma Sources Insight January 2025
